BioSpace News Archive

Drug Development

Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma’s Oxygen Therapeutic in Phase IIa Clinical Trial

NuvOx Pharma, a Tucson-based biotechnology company developing NanO2™ emulsion for oxygen delivery, has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).

June 29, 2020
·
2 min read
Business

The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome (“IBS”) Diagnostic-Guided Therapy (“DGT”) clinical trial

Biomerica Inc. (NASDAQ: BMRA) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Houston (“UTH”) to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.

June 29, 2020
·
8 min read
Policy

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

Alterity Therapeutics is pleased to announce that it has received guidance from the US Food and Drug Administration in relation to the development pathway for ATH434, the company’s lead compound for the treatment of Multiple System Atrophy, a Parkinsonian disorder.

June 29, 2020
·
2 min read